
Bard Loses Appeal, Set to Pay $2 Million in Mesh Verdict
C.R. Bard, Inc. lost its appeal of a jury's $2 million verdict in Fourth Circuit appellate court on Thursday.
C.R. Bard, Inc. lost its appeal of a jury's $2 million verdict in Fourth Circuit appellate court on Thursday.
Last week, the Food and Drug Administration (FDA) reclassified transvaginal mesh products as class III or 'high risk' medical devices.
It's been a mixed couple of weeks for transvaginal mesh lawsuits. While seven different manufacturers continue to face multidistrict litigations in West Virginia
Boston Scientific Corp. was hit with a $73.4 million verdict earlier this month after a jury found that the company's Obtryx transvaginal sling was defective
A controversial medical device used in hysterectomies and myomectomies is being recalled by Johnson & Johnson's Ethicon Endo-Surgery unit following FDA warnings
The FDA has announced it will not be recalling or banning transvaginal mesh products – or at least not yet. What prompted this announcement?
This week, J&J agreed to pay out $4 million to settle Oregon's claims that subsidiary DePuy Orthopaedics made false claims when advertising and selling its now recalled
What's the best advice for companies facing legal action? Admit nothing and deny everything, apparently. Endo International Plc. has certainly taken that to heart
There are 44,020 reasons not to trust transvaginal mesh – that's the total number of cases filed against seven different manufacturers as of March 13, 2014.
Endo has revealed it is preparing for the outcome of its vaginal mesh MDL with a $520 million reserve.